High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Informed consent

• Stable hypertension defined as no new antihypertensive medication started within 6 weeks of Visit 1

• Minimum 6-month history of hypertension and primary glomerular disease

• Hypertensive nephrosclerosis

• Diabetic nephropathy with stable proteinuria as defined by ≥ 1g/24 hours on more than one occasion within 6 months prior to Visit 1

Exclusion Criteria:

• Persistent hypertension

• New anti-hypertensive medications started within 6 weeks of Visit 1

• Significant cardiac disease or Liver disease

• Females of childbearing potential without reliable contraception

• Pregnant women and women who are breast-feeding